Resistant Pseudomonas Aeruginosa Infections Drugs Market, Global Outlook and Forecast 2022-2028
Report Code: KNJ1281469 No. of Pages: 74 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
This report contains market size and forecasts of Resistant Pseudomonas Aeruginosa Infections Drugs in global, including the following market information:
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Resistant Pseudomonas Aeruginosa Infections Drugs companies in 2021 (%)
The global Resistant Pseudomonas Aeruginosa Infections Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Semi-Synthetic Penicillin Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs include ContraFect Corp, Inhibrx LP, Achaogen Inc, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Novartis AG, AmpliPhi Biosciences Corp, Biolytics Pharma and Shionogi & Co Ltd. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Resistant Pseudomonas Aeruginosa Infections Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment Percentages, by Type, 2021 (%)
Semi-Synthetic Penicillin
Cephalosporin
Lactam Drugs
Others
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Home Care
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Resistant Pseudomonas Aeruginosa Infections Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Resistant Pseudomonas Aeruginosa Infections Drugs revenues share in global market, 2021 (%)
Key companies Resistant Pseudomonas Aeruginosa Infections Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Resistant Pseudomonas Aeruginosa Infections Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
ContraFect Corp
Inhibrx LP
Achaogen Inc
LegoChem Biosciences Inc
Melinta Therapeutics Inc
Novartis AG
AmpliPhi Biosciences Corp
Biolytics Pharma
Shionogi & Co Ltd
1 Introduction to Research & Analysis Reports
1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Overall Market Size
2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size: 2021 VS 2028
2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales: 2017-2028
3 Company Landscape
3.1 Top Resistant Pseudomonas Aeruginosa Infections Drugs Players in Global Market
3.2 Top Global Resistant Pseudomonas Aeruginosa Infections Drugs Companies Ranked by Revenue
3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Companies
3.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Companies
3.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Resistant Pseudomonas Aeruginosa Infections Drugs Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Resistant Pseudomonas Aeruginosa Infections Drugs Players in Global Market
3.8.1 List of Global Tier 1 Resistant Pseudomonas Aeruginosa Infections Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Resistant Pseudomonas Aeruginosa Infections Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Markets, 2021 & 2028
4.1.2 Semi-Synthetic Penicillin
4.1.3 Cephalosporin
4.1.4 Lactam Drugs
4.1.5 Others
4.2 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue & Forecasts
4.2.1 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2022
4.2.2 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2023-2028
4.2.3 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
4.3 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales & Forecasts
4.3.1 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2022
4.3.2 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2023-2028
4.3.3 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
4.4 By Type - Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Home Care
5.2 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue & Forecasts
5.2.1 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2022
5.2.2 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2023-2028
5.2.3 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
5.3 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales & Forecasts
5.3.1 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2022
5.3.2 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2023-2028
5.3.3 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
5.4 By Application - Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2021 & 2028
6.2 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue & Forecasts
6.2.1 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2022
6.2.2 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2023-2028
6.2.3 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share, 2017-2028
6.3 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales & Forecasts
6.3.1 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2022
6.3.2 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2023-2028
6.3.3 By Region - Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2028
6.4.2 By Country - North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2028
6.4.3 US Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.4.4 Canada Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.4.5 Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2028
6.5.2 By Country - Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2028
6.5.3 Germany Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5.4 France Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5.5 U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5.6 Italy Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5.7 Russia Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5.8 Nordic Countries Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.5.9 Benelux Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2028
6.6.2 By Region - Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2028
6.6.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.6.4 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.6.5 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.6.6 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.6.7 India Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2028
6.7.2 By Country - South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2028
6.7.3 Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.7.4 Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales, 2017-2028
6.8.3 Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.8.4 Israel Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.8.5 Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
6.8.6 UAE Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 ContraFect Corp
7.1.1 ContraFect Corp Corporate Summary
7.1.2 ContraFect Corp Business Overview
7.1.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.1.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.1.5 ContraFect Corp Key News
7.2 Inhibrx LP
7.2.1 Inhibrx LP Corporate Summary
7.2.2 Inhibrx LP Business Overview
7.2.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.2.4 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.2.5 Inhibrx LP Key News
7.3 Achaogen Inc
7.3.1 Achaogen Inc Corporate Summary
7.3.2 Achaogen Inc Business Overview
7.3.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.3.4 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.3.5 Achaogen Inc Key News
7.4 LegoChem Biosciences Inc
7.4.1 LegoChem Biosciences Inc Corporate Summary
7.4.2 LegoChem Biosciences Inc Business Overview
7.4.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.4.4 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.4.5 LegoChem Biosciences Inc Key News
7.5 Melinta Therapeutics Inc
7.5.1 Melinta Therapeutics Inc Corporate Summary
7.5.2 Melinta Therapeutics Inc Business Overview
7.5.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.5.4 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.5.5 Melinta Therapeutics Inc Key News
7.6 Novartis AG
7.6.1 Novartis AG Corporate Summary
7.6.2 Novartis AG Business Overview
7.6.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.6.4 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.6.5 Novartis AG Key News
7.7 AmpliPhi Biosciences Corp
7.7.1 AmpliPhi Biosciences Corp Corporate Summary
7.7.2 AmpliPhi Biosciences Corp Business Overview
7.7.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.7.4 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.7.5 AmpliPhi Biosciences Corp Key News
7.8 Biolytics Pharma
7.8.1 Biolytics Pharma Corporate Summary
7.8.2 Biolytics Pharma Business Overview
7.8.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.8.4 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.8.5 Biolytics Pharma Key News
7.9 Shionogi & Co Ltd
7.9.1 Shionogi & Co Ltd Corporate Summary
7.9.2 Shionogi & Co Ltd Business Overview
7.9.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Major Product Offerings
7.9.4 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Revenue in Global (2017-2022)
7.9.5 Shionogi & Co Ltd Key News
8 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity, Analysis
8.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity, 2017-2028
8.2 Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Resistant Pseudomonas Aeruginosa Infections Drugs Supply Chain Analysis
10.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Value Chain
10.2 Resistant Pseudomonas Aeruginosa Infections Drugs Upstream Market
10.3 Resistant Pseudomonas Aeruginosa Infections Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Resistant Pseudomonas Aeruginosa Infections Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com